Amgen's Repatha: A Significant Step Towards Broader Cardiovascular Protection in Europe

On July 30, 2026, Amgen received favorable news regarding its PCSK9 inhibitor, Repatha (evolocumab), as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended its expanded use. This recommendation is particularly significant for adults with established atherosclerotic cardiovascular disease or those at high risk of developing such conditions, aiming to reduce cardiovascular risks by lowering levels of LDL-C (low-density lipoprotein cholesterol).

The Importance of Repatha

Repatha is the only PCSK9 inhibitor that has shown a considerable capability to reduce the risk of experiencing a first heart attack or stroke, as indicated by results from the Phase 3 VESALIUS-CV clinical trial, which included over 12,000 patients. In this landmark trial, patients with a high cardiovascular risk and no previous heart attack or stroke significantly benefited from Repatha when added to statin therapy or other LDL-C reduction treatments. The findings demonstrate a compelling case for Repatha's role in reshaping cardiovascular care in Europe, especially for patients struggling to reach recommended LDL-C levels despite available therapies.

Dr. Paul Burton, Chief Medical Officer at Amgen, emphasized the unmet need in Europe, noting that a significant number of high-risk cardiovascular patients fail to achieve optimal LDL-C levels. He also pointed out that the favorable opinion of the CHMP is a step closer to making Repatha accessible to more patients who could truly benefit from its capabilities. If approved by the European Commission, this expanded indication is poised to redefine cardiovascular management for appropriate patients.

Unraveling the Risk of Cardiovascular Diseases

Globally, cardiovascular diseases continue to be the leading cause of death. Most individuals who face their first cardiovascular event exhibit at least one traditional risk factor, with elevated LDL-C being one of the most modifiable risks for heart attacks or strokes. Despite guidelines from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) advocating for intensive LDL-C reduction based on cardiovascular risk, many high-risk patients remain above the recommended LDL-C levels, indicating a crucial area for therapeutic intervention.

Repatha was initially approved in the European Union in 2015 for treating primary hypercholesterolemia and mixed dyslipidemia. Its current recommendation for broader use is supported by the robust clinical evidence generated from the ongoing efforts in the field of cardiovascular health.

The VESALIUS-CV Trial Details

The VESALIUS-CV trial was a randomized, double-blind, placebo-controlled study focused on adults with high cardiovascular risk, specifically those without prior heart attacks or strokes. The study aims to evaluate the impact of LDL-C reduction through evolocumab on major adverse cardiovascular events (MACE). Findings published in the New England Journal of Medicine highlighted that Repatha achieved a relative risk reduction of 25% in composite cardiovascular events, alongside a notable 36% reduction in heart attacks. The trial's parameters and results underscore the innovative capacity of Repatha in preventing severe cardiovascular incidents among high-risk populations.

The results from VESALIUS-CV indicated that patients experienced significant reductions in LDL-C levels when treated with evolocumab combined with maximally tolerated doses of statins and/or ezetimibe, showcasing average LDL-C levels drastically lower than those observed in placebo groups.

Amgen's Ongoing Commitment to Cardiovascular Innovation

Amgen continues to respond to the pressing need for improved cardiovascular and metabolic therapies, leveraging over 40 years of expertise in human biology. The firm is strategically positioned to impact cardiometabolic care significantly, as it aims to mitigate the persistent cardiovascular risk associated with elevated LDL-C and related disorders, which can lead to severe outcomes or mortality.

With its continued dedication to research and innovation, Amgen acknowledges the importance of addressing interconnected factors that drive cardiovascular and metabolic diseases. Not only does the company provide Repatha to millions of patients globally, but it is also on the verge of introducing potentially revolutionary treatments such as MariTide and olpasiran to further advance care in this vital therapeutic area.

Conclusion

The CHMP's favorable opinion on Repatha signifies a pivotal moment in expanding access to vital cardiovascular treatments in Europe. With the anticipated European Commission approval, Repatha's integration into broader therapeutic regimens may substantially enhance patient outcomes and reshape the landscape of cardiovascular healthcare, promoting a healthier future for high-risk populations.